Combined Therapeutic Modality with Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Transplantation (ASCT) Leads to Excellent Response Rate and High Probability of Molecular Remission in Chronic Lymphocytic Leukemia (CLL) Patients

Abstrakt

Rituximab, Fludarabin, Cyclophosphamide, Stem Cell Transplantation, Chronic Lymphocytic Leukemia (CLL)